Welcome to our dedicated page for Kkr & Co news (Ticker: KKR), a resource for investors and traders seeking the latest updates and insights on Kkr & Co stock.
KKR & Co Inc (KKR) is a leading global alternative asset manager with a 45+ year track record in private equity, credit, and infrastructure investments. This page provides investors and financial professionals with timely access to official press releases, earnings reports, and strategic updates directly from KKR.
Key resources include: Quarterly earnings announcements, merger & acquisition disclosures, leadership updates, and partnership developments. Our curated feed ensures you stay informed about KKR's global initiatives across private markets, real estate, and insurance solutions through Global Atlantic Financial Group.
Bookmark this page for verified updates on KKR's investment activities, ESG commitments, and capital allocation strategies. All content is sourced from official company communications to ensure accuracy and compliance with financial disclosure standards.
THL Partners has announced a definitive agreement to acquire Headlands Research from KKR (NYSE:KKR). Headlands Research operates a multinational network of clinical trial sites across North America, specializing in central nervous system disorders, vaccines, and metabolic diseases.
KKR founded Headlands in 2018 through its Health Care Strategic Growth Fund, focusing on transforming the clinical trial site industry and improving trial inclusivity. Under KKR's ownership, Headlands achieved significant growth through acquisitions, operational excellence, and network integration.
The acquisition will be executed through THL's Fund IX, with the transaction expected to close in 2025. THL plans to support Headlands' expansion, enhance its technology infrastructure, and strengthen its ability to deliver diverse clinical trial data for pharmaceutical and biotech sponsors.
KKR (NYSE:KKR) has announced its credit funds will serve as lead investors in financing Harvest Partners' growth investment in Med-Metrix, a technology-enabled Revenue Cycle Management (RCM) solutions provider. KKR Capital Markets is acting as Left Lead Arranger and Bookrunner for the transaction.
Med-Metrix's current management team, led by CEO Joseph Davi, will maintain leadership while retaining significant ownership. Previous owner A&M Capital (AMC) will keep a minority stake and provide additional investment. KKR previously served as the sole lender in AMC's 2021 acquisition of Med-Metrix.
Founded in 2010, Med-Metrix provides end-to-end RCM services and technology solutions to healthcare systems and physician groups across the United States through its proprietary platform.
FS KKR Capital Corp. (NYSE: FSK) reported its Q2 2025 financial results, announcing a Q3 2025 distribution of $0.70 per share. The company posted net investment income of $0.62 per share, down from $0.67 in Q1 2025. FSK's net asset value decreased to $21.93 per share from $23.37, with a total net realized and unrealized loss of $1.36 per share.
The company's investment portfolio totaled $13.6 billion, with 64.1% in senior secured securities. FSK maintained a weighted average yield of 10.8% on accruing debt investments. The quarter saw $1.4 billion in new purchases versus $1.65 billion in sales and repayments. Non-accrual investments increased to 3.0% of the portfolio at fair value, up from 2.1% in Q1.
FSK also secured an amended Senior Secured Revolving Credit Facility, increasing it to $4.7 billion with extended maturity to July 2030 and a 10-basis-point reduction in borrowing rate.
KKR (NYSE:KKR) has announced a strategic recapitalization of DentalXChange (DXC), a leading dental revenue cycle management solutions provider. DXC processes over 2 billion transactions annually in the U.S. dental market. The deal involves Bregal Sagemount's exit from their investment in DXC.
The investment, made through KKR's Ascendant Fund, aims to accelerate DXC's product development and growth. CEO Paul Kaiser will continue leading the company, with plans to expand automation and AI capabilities. Notably, KKR will implement a broad-based equity ownership program allowing all DXC employees to participate in the company's value creation.
KKR (NYSE: KKR) has announced the pricing of $900 million in senior notes with a 5.100% interest rate, maturing in 2035. The notes will be guaranteed by KKR Group Partnership L.P. and are expected to close on August 7, 2025.
The company plans to use the proceeds primarily for repurchasing and refinancing existing debt of its subsidiary, KKR Financial Holdings LLC, with any remaining funds allocated for general corporate purposes. The offering is being managed by a consortium of financial institutions including Morgan Stanley, Goldman Sachs, HSBC Securities, KKR Capital Markets, and UBS Investment Bank.
KKR & Co. Inc. (NYSE: KKR) has announced the commencement of a senior notes offering. The notes will be senior obligations of KKR and fully guaranteed by KKR Group Partnership L.P.
The company plans to use the proceeds primarily for repurchasing and refinancing existing debt of its subsidiary, KKR Financial Holdings LLC, with any remaining funds allocated for general corporate purposes. The offering is being conducted through a shelf registration statement with the SEC, with Morgan Stanley, Goldman Sachs, HSBC Securities, KKR Capital Markets, and UBS Investment Bank serving as joint book-running managers.
Clinisupplies Limited, backed by KKR (NYSE:KKR), has announced the acquisition of the Renew Inserts business from Renew Medical Inc. and Renew Medical UK Limited. The strategic acquisition aims to expand Clinisupplies' bowel management portfolio and enhance its chronic care services.
The deal aligns with Clinisupplies' mission to help patients with continence issues through comprehensive products and services. The acquisition is supported by KKR's Health Care Strategic Growth Fund II, a $4.0 billion fund, with KKR having invested over $20 billion in the healthcare sector since 2004.
KKR & Co. (NYSE: KKR), a leading global investment firm, has announced its second quarter 2025 financial results. The detailed results have been made available on the company's investor relations website.
The company will host a conference call on July 31, 2025, at 9:00 a.m. ET to discuss the financial results. Investors can access the call through U.S. toll-free number (877) 407-0312 or international number +1 (201) 389-0899. A live webcast will be available through KKR's Investor Center, with a replay accessible approximately one hour after the broadcast.
KKR (NYSE:KKR) and Energy Capital Partners (ECP) have announced the development of a 190 MW hyperscale data center campus in Bosque County, Texas, marking their first investment from a $50 billion strategic partnership. The project, co-located with Calpine's natural gas power plant, represents a total investment of approximately $4 billion.
The campus will span over 700,000 square feet with an initial IT capacity of 144 megawatts. Developed through a joint venture with CyrusOne, the facility will feature climate-neutral initiatives and is expected to be operational by Q4 2026. The project establishes a new model for integrated AI-ready infrastructure, combining digital capacity with dedicated power supply in one of the nation's fastest-growing compute corridors.
KKR (NYSE:KKR) has announced the acquisition of a majority stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company. HCRx, founded in 2006, has committed over $7 billion in capital and currently manages approximately $3 billion in assets across more than 55 products and 10 therapeutic areas.
The strategic acquisition will enhance KKR's capabilities in biopharma royalty and credit investing while expanding its life sciences presence. HCRx's current Chairman and CEO Clarke Futch will continue leading the team while maintaining a substantial minority interest. KKR has invested more than $20 billion of equity capital in the healthcare sector since 2004, with investments in companies like BridgeBio Pharma, Dawn Bio, and Immedica Pharma.
FAQ
What is the current stock price of Kkr & Co (KKR)?
What is the market cap of Kkr & Co (KKR)?
